Fundraising FoxIsoPlexis
New Haven, US · Founded 2014 · Delaware corporation · 5 known investors
Find your way into IsoPlexis
Sign up to see every warm intro you have to IsoPlexis
- Paths you didn't know you had: your email and LinkedIn already hold routes to the IsoPlexis team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
IsoPlexis offers the Cell Analysis Suite (CAS), software for its Beacon optofluidic platform that lets researchers design, automate, and analyze functional live single-cell workflows. It serves life-science researchers working in areas such as antibody discovery, cell line development, T cell profiling, and adoptive cell therapy.
Founders & leadership
IsoPlexis was founded in 2014 by Rong Fan, Sean McKay, and Sean Mackay.
Board
DW
Daniel WagnerBoard director
JC
GH
Gregory HoBoard director
Investors · 5
Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M
How we know: Connecticut Innovations's portfolio page · press coverage · Not right? Tell us
Ally Bridge GroupreportedNew York
How we know: funding news · Not right? Tell us
Ironwood CapitalreportedAvon · $10M – $50M
How we know: press coverage · Not right? Tell us
Northpond VenturesreportedBethesda · $100K – $5Mvia Sharon Kedar · board
How we know: board seat on SEC Form D · press coverage · Not right? Tell us
Spring Mountain CapitalreportedNew York
How we know: press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$127M disclosed across 7 of 8 rounds · 2014–2021
- Undisclosed amountIPOOct 2021Source ↗
▶$7.5MraisedJan 2021 · 1 investors · Other TechnologyRule 506(b)
▶$7.5MraisedJan 2021 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- John StrahleyExecutive Officer
- Sean MackayExecutive Officer, Director
- John ConleyDirector
- GREGORY HODirector
- DANIEL WAGNERDirector
- JAMES HEATHDirector
- MICHAEL EGHOLMDirector
- SHARON KEDARDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$85MraisedJan 2021 · 10 investors · Other TechnologyRule 506(b)
▶$85MraisedJan 2021 · 10 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- DANIEL WAGNERDirector
- GREGORY HODirector
- John ConleyDirector
- Sean MackayExecutive Officer, Director
- MICHAEL EGHOLMDirector
- SHARON KEDARDirector
- John StrahleyExecutive Officer
- JAMES HEATHDirector
- Offering amount
- $85M
- Amount sold
- $85M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.6MraisedNov 2018 · 6 investors · Other TechnologyRule 506(b)
▶$19.6MraisedNov 2018 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel WagnerDirector
- Sean MackayExecutive Officer, Director
- James HeathDirector
- Gregory HoDirector
- John ConleyDirector
- Offering amount
- $25M
- Amount sold
- $19.6M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$5.4MraisedAug 2017 · 4 investors · Other TechnologyRule 506(b)
▶$5.4MraisedAug 2017 · 4 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- James HeathDirector
- John ConleyDirector
- Sean MackayExecutive Officer, Director
- Daniel WagnerDirector
- Gregory HoDirector
- Offering amount
- $6.4M
- Amount sold
- $5.4M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$5.7MraisedJun 2016 · 5 investors · Other TechnologyRule 506(b)
▶$5.7MraisedJun 2016 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Sean McKayExecutive Officer, Director
- James HeathDirector
- Rong FanDirector
- Gregory HoDirector
- Daniel WagnerDirector
- Offering amount
- $8M
- Amount sold
- $5.7M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$2.4MraisedMay 2015 · 4 investors · Other TechnologyRule 506(b)
▶$2.4MraisedMay 2015 · 4 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel WagnerDirector
- John ConleyDirector
- Gregory HoDirector
- Rong FanDirector
- Sean McKayExecutive Officer, Director
- Offering amount
- $3.8M
- Amount sold
- $2.4M
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1.3MraisedJul 2014 · 7 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJul 2014 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean MackayExecutive Officer, Director
- Offering amount
- $1.7M
- Amount sold
- $1.3M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 17 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $163.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $162.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $164K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $164K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $160.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $182K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does IsoPlexis do?
- IsoPlexis offers the Cell Analysis Suite (CAS), software for its Beacon optofluidic platform that lets researchers design, automate, and analyze functional live single-cell workflows. It serves life-science researchers working in areas such as antibody discovery, cell line development, T cell profiling, and adoptive cell therapy.
- Who founded IsoPlexis?
- IsoPlexis was founded by Rong Fan, Sean McKay, Sean Mackay in 2014.
- Who are IsoPlexis's investors?
- IsoPlexis's investors include Connecticut Innovations, Ally Bridge Group, Ironwood Capital, Northpond Ventures, Spring Mountain Capital.
- How much funding has IsoPlexis raised?
- IsoPlexis has disclosed $127M raised across 7 of its 8 known rounds.
- Where is IsoPlexis headquartered?
- IsoPlexis is headquartered in New Haven, US.